Efficacy and safety of ketamine in bipolar depression: A systematic review
This review (2017) compared the safety and efficacy of ketamine for bipolar depression across scientific studies (1 clinical trial, 4 case studies, 5 cohort studies), which showed that symptoms are reduced swiftly and effectively in response to treatment, but they reappear relatively quickly within 3-14 days depending on the scale used to measure symptoms. Ketamine may be considered safe and effective for treating some cases of bipolar depression, although it has a short duration of action, in the absence of confirming studies designed specifically for bipolar depression.
Authors
- Alberich, S.
- Martínez-Cengotitabengoa, M.
- López, P.
Published
Abstract
The depression is the most prevalent state throughout the life of the bipolar patient. Ketamine has been shown to be an effective and rapid treatment for depression. The objective of the present work is to perform a systematic review on the efficacy and safety of ketamine as treatment of bipolar depression, as well as its different patterns of administration. The search found 10 relevant manuscripts that met the inclusion criteria: one clinical trial, 5 cohort studies, and 4 case reports. Intravenous infusion was used in 60% of the studies. According to data, ketamine seems to be an effective and safe treatment for bipolar depression, although the length of its effect is short. Adverse effects observed generally occurred at the time of infusion, and tended to completely disappear within 1-2 h. Therefore, more studies are necessary to explore new patterns of administration, as well as on its safety and adverse effects.
Research Summary of 'Efficacy and safety of ketamine in bipolar depression: A systematic review'
Introduction
Bipolar disorder is a highly disabling and costly condition in which depressive states are the most common mood component over the lifetime. Although established treatments exist for bipolar depression, a substantial proportion of patients remain insufficiently responsive or intolerant to available options, and there is a pressing need for rapidly acting antidepressant interventions because of suicide risk. Research over the past decade has implicated the glutamatergic system and the N-methyl-d-aspartate (NMDA) receptor in antidepressant mechanisms, motivating interest in NMDA antagonists. This systematic review aims to summarise the evidence on the efficacy and safety of ketamine for bipolar depression and to describe different administration patterns. The focus is on prospective human studies published in English or Spanish between January 2012 and October 2015 that specifically evaluated ketamine in patients with bipolar disorder and depressive episodes.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Compound
- Topics
- APA Citation
Alberich, S., Martínez-Cengotitabengoa, M., López, P., Zorrilla, I., Núñez, N., Vieta, E., & González-Pinto, A. (2017). Efficacy and safety of ketamine in bipolar depression: A systematic review. Revista de Psiquiatría y Salud Mental (English Edition), 10(2), 104-112. https://doi.org/10.1016/j.rpsmen.2017.05.004
References (8)
Papers cited by this study that are also in Blossom
Zarate, C. A., Brutsche, N. E., Ibrahim, L. et al. · Biological Psychiatry (2012)
Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)
Murrough, J. W., Iosifescu, D. V., Chang, L. C. et al. · American Journal of Psychiatry (2013)
Nutt, D. J. · Journal of Psychopharmacology (2015)
Murrough, J. W., Perez, A. M., Pillemer, S. et al. · Biological Psychiatry (2012)
Caddy, C., Giaroli, G., White, T. P. et al. · Therapeutic Advances in Psychopharmacology (2013)
Coyle, C. M., Laws, K. R. · Human Psychopharmacology (2015)
Fond, G., Loundou, A., Macgregor, A. et al. · Psychopharmacology (2014)
Cited By (7)
Papers in Blossom that reference this study
Meshkat, S., Cao, B., Teopiz, K. M. et al. · Journal of Affective Disorders (2023)
Shamabadi, A., Ahmadzade, A., Hasanzadeh, A. · British Journal of Clinical Pharmacology (2022)
Bahji, A., Zarate, C. A., Vazquez, G. H. · International Journal of Neuropsychopharmacology (2021)
Bahji, A., Vazquez, G. H., Zarate, C. A. · Journal of Affective Disorders (2021)
Martial, C., Cassol, H., Charland-Verville, V, Erowid, E. et al. · Consciousness and Cognition (2019)
Cohen, I. V., Makunts, T., Atayee, R. et al. · Scientific Reports (2017)
López-Díaz, A., Fernández-González, J. L., Luján-Jiménez, J. E. et al. · Therapeutic Advances in Psychopharmacology (2017)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.